Fundraising Fox

Argonaute

Cardiff, GB · 1 known investors

Argonaute RNA develops siRNA-based (RNA interference) therapeutics, with a pipeline focused on cardiovascular disease, combining oligonucleotide chemistry and drug development expertise. The UK biotech takes early-stage academic ideas through preclinical and clinical development.

Founders & leadership

AP
Anthony ParkerinCo-founder
RT
Richard TompkinsinCo-founder
MK
Mike KhaninCEO

Investors · 1

Frequently asked questions

What does Argonaute do?
Argonaute RNA develops siRNA-based (RNA interference) therapeutics, with a pipeline focused on cardiovascular disease, combining oligonucleotide chemistry and drug development expertise. The UK biotech takes early-stage academic ideas through preclinical and clinical development.
Who founded Argonaute?
Argonaute was founded by Anthony Parker, Richard Tompkins.
Who are Argonaute's investors?
Argonaute's investors include Oxford Investment Opportunity Network (OION).
Where is Argonaute headquartered?
Argonaute is headquartered in Cardiff, GB.